Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026)
Penumbra's (PEN) quarterly Total Non-Current Liabilities came in at $411.4 million in Q1 2026, up 12.87% year-on-year from $364.5 million in Q1 2025, and up 6.41% on a QoQ basis from $386.6 million in Q4 2025.
Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Total Non-Current Liabilities data on file, last reported at $411.4 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 12.87% year-over-year to $411.4 million in Q1 2026; TTM through Mar 2026 was $411.4 million, a 12.87% increase from a year earlier, with the FY2025 full-year figure at $386.6 million, up 5.3% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $411.4 million, up from $386.6 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for PEN reached as high as $411.4 million in Q1 2026 and fell as low as $338.7 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $366.8 million across 5 years, with a median of $365.7 million in 2024.
- Across the five-year window, Total Non-Current Liabilities soared 85.68% in 2022 and dropped 1.61% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $368.8 million in 2022, then rose by 0.9% to $372.1 million in 2023, then fell by 1.32% to $367.1 million in 2024, then gained by 5.3% to $386.6 million in 2025, then climbed by 6.41% to $411.4 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $411.4 million in Q1 2026, $386.6 million in Q4 2025, and $371.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 411.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 411.38 Mn |
| Dec 31, 2025 | 386.60 Mn |
| Sep 30, 2025 | 371.14 Mn |
| Jun 30, 2025 | 363.04 Mn |
| Mar 31, 2025 | 364.48 Mn |
| Dec 31, 2024 | 367.14 Mn |
| Sep 30, 2024 | 365.39 Mn |
| Jun 30, 2024 | 365.71 Mn |
| Mar 31, 2024 | 370.44 Mn |
| Dec 31, 2023 | 372.05 Mn |
| Sep 30, 2023 | 360.97 Mn |
| Jun 30, 2023 | 362.70 Mn |
| Mar 31, 2023 | 367.59 Mn |
| Dec 31, 2022 | 368.75 Mn |
| Sep 30, 2022 | 344.55 Mn |
| Jun 30, 2022 | 354.41 Mn |
| Mar 31, 2022 | 338.66 Mn |
| Dec 31, 2021 | 286.77 Mn |
| Sep 30, 2021 | 281.00 Mn |
| Mar 31, 2021 | 182.39 Mn |